associated with dental care (Moore, 2007) . Of many drug delivery systems, percutaneous drug delivery can provide controlled delivery of drugs. However, in case of their application such as ointments and creams, it is diffi cult to expect their effects for a signifi cant period of time, because they are easily removed by wetting, movement and contacting. Therefore, the new formulations that have suitable bioadhesion were needed to enhance local anesthetic effects.
INTRODUCTION
Local anesthetics are often used to alleviate pain after surgery, medical procedures and dental pains (Smith et al., 1999) . They are also used in the control of postoperative pain and in the therapy of chronic pain (Dahm et al., 2000) and can be used for regional control of major pain. In relieving local pains, ropivacaine, one of local anesthetics belonging to the amide group, has been used. Of many drug delivery systems, percutaneous drug delivery has some advantages of providing the controlled delivery of the drug for an extended period of time.
One of these local anesthetic drugs is ropivacaine, which is characterized by its long action and high therapeutic power (Ritchie et al., 1989) . There is a substantial population with intractable pain that is not responsive to opioids that require non-opioid agents, including local anesthetics (Dahm et al., 2000; Tsai et al., 2000) . Ropivacaine plays a valuable role in the overall management of surgical and postoperative pain
In relieving local pains, ropivacaine has been widely used. In case of their application such as ointments and creams, it is diffi cult to expect their effects for a signifi cant period of time, because they are easily removed by wetting, movement and contacting. Therefore, the new formulations that have suitable bioadhesion were needed to enhance local anesthetic effects. The effect of drug concentration and temperature on drug release was studied from the prepared 1.5% Carboxymethyl cellulose (CMC) (150 MC) gels using synthetic cellulose membrane at 37 ± 0.5 o C. As the drug concentration and temperature increased, the drug release increased. A linear relationship was observed between the logarithm of the permeability coeffi cient and the reciprocal temperature. The activation energy of drug permeation was 3.16 kcal/mol for a 1.5% loading dose. To increase the skin permeation of ropivacaine from CMC gel, enhancers such as saturated and unsaturated fatty acids, pyrrolidones, propylene glycol derivatives, glycerides, and non-ionic surfactants were incorporated into the ropivacaine-CMC gels. Among the enhancers used, polyoxyethylene 2-oleyl ether showed the highest enhancing effects. For the effi cacy study, the anesthetic action of the formulated ropivacaine gel containing an enhancer and vasoconstrictor was evaluated with the tail-fl ick analgesimeter. According to the rat tail-fl ick test, 1.5% drug gels containing polyoxyethylene 2-oleyl ether and tetrahydrozoline showed the best prolonged local analgesic effects. In conclusion, the enhanced local anesthetic gels containing penetration enhancer and vasoconstrictor could be developed using the bioadhesive polymer. esthetic effects of the formulated ropivacaine-CMC gels containing polyoxyethylene 2-oleyl ether was evaluated in the tail fl ick anesthetic test.
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The objective of this study was to develop a bioadhesive gel formulation showing the enhanced local anesthetic effi cacy.
MATERIALS AND METHODS

Materials
Ropivacaine hydrochloride was supplied from Dong-Woo Co. Ltd. (Korea). Carboxymethyl cellulose sodium was obtained from Bolak Co. Ltd. (Korea). Polyethylene glycol, lauric acid, oleic acid, caprylic acid, myristic acid, linoleic acid, stearic acid, palmitic acid, 2-pyrrolidone, 1-methyl-2-pyrrolidone, polyoxyethylene-2-stearyl ether (Brij 72), polyoxyethylene-23-lauryl ether (Brij 35) and polyoxyethylene-2-oleyl ether (Brij 92) were purchased from Sigma-Aldrich Co. (USA). Oleyl macrogol-6 glycerides, caprylocaproyl mcarogol-8 glycerides, propylene glycol laurate, and propylene glycol monolaurate were gift from Gattefose (France). Methanol was HPLC grade from J.T.Baker Inc. (USA). All reagents of analytical grade were used without further purifi cation.
Measurement of viscosity and bioadhesive strength
The viscosity and bioadhesive force of various types of CMC were measured at 1.5% CMC concentration, respectively. The viscosity was measured with an MV II at a shear rate of 1.8 1/s using rotary viscometer (Haake Co, Germany) and sample equilibration took approximately 45 sec. The viscosity of sample was then determined by multiplying the observed reading. The bioadhesive capacity was determined by measuring the maximum detachment force using an Auto Peeling Tester (C.K. Trading, Korea). Cyanoacrylate adhesive was used to fi x the intestinal mucosa to the upper and lower support. The CMC gel was placed on the both supports. Upon contact of the gel-intestine mucosa, a force was applied for fi ve minutes. This procedure was performed at a speed of 150 mm/min until the complete detachment of the components was achieved. The adhesion work was calculated as N (Newton force).
Drug release from the CMC gels through cellulose membrane
The in vitro release of ropivacaine from the CMC gels was examined by using the modifi ed Franz diffusion cell. The diameter of the cell was 2 cm, providing 3.14 cm 2 effective constant area between the membrane and the bulk solution of 20 ml. The fl ux of ropivacaine from the CMC gels was determined using the phosphate buffer solution (pH 7.4) as a receptor. The synthetic cellulose membrane was mounted on the receptor compartment of the diffusion cell.
Five grams of prepared CMC gels containing ropivacaine was placed in intimate contact with the cellulose membrane and the donor cap was covered with a parafi lm and clamped. The sampling port was sealed with a parafi lm to prevent the evaporation of the receptor medium. The receptor solution, phosphate buffer solution, was maintained at 37 o C by a circulating water bath and stirred by a magnetic stirring bar. The donor compartment was maintained at ambient temperature. The effect of drug concentration on its release from the gels was studied according to drug concentration of 0.5, 1, 1.5, 2 and 2.5% (w/w), and the effects of temperature on drug release was performed at 27, 32, 37 and 42 o C by thermostated water bath. All samples (20 ml) from the receptor compartment were withdrawn at predetermined intervals to maintain a sink condition, and immediately replaced by the same amount of fresh phosphate buffer solution.
HPLC determination of ropivacaine
Ropivacaine was assayed by HPLC method. The HPLC system was consisted with pump (Knauer, DE/K-120, USA), ultraviolet detector (Waters 484, USA), C 18 column (250×4.6 mm, 5 μm), degaser, and an integrator (D520A, Youngin scientifi c Co. Ltd. Korea). The mobile phase was composed with a mixture of methanol, water, phosphoric acid (30:70:0.1 v/v/v). A fl ow rate of 1.0 ml/min yielded an operation pressure of -1,000 psi. The UV detector was operated at the wavelength of 220 nm. Under these conditions, ropivacaine peak appeared at the retention time of 4.2 min.
Preparation of ropivacaine-CMC gels containing an enhancer
1.5 grams of carboxymethyl cellulose sodium was dissolved in hot water to make 35 g. 1.5% ropivacaine and 5% enhancer were added with vigorous stirring to the above CMC solutions and water was added to make 100 g.
Skin preparation
A male rat (Sprague Dawley rat strain) was sacrifi ced by snapping the spinal cord at the neck. The hair of abdominal area was carefully removed with an electric clipper. A square section of the abdominal skin was excised. After incision, the adhering fats and other visceral debris in the skin were carefully removed from the undersurface with tweezers. The excised skin was used immediately.
Penetration of ropivacaine from the CMC gels through rat skins
The drug permeation through rat skin from the 1.5% ropivacaine-CMC gel formulations was carried out at 37 o C using phosphate buffer solution (pH 7.4) as a receptor medium. The freshly excised full-thickness skin sample was mounted on the receptor site of the diffusion cell with the stratum corneum side facing upwards into the donor compartment and the dermal side facing downwards into the receptor compartment. Appropriate amount of gels was placed on the stratum corneum side and covered with round glass plate and clamped. Receptor medium, phosphate buffer solution (pH 7.4) was maintained 37 o C by a circulating water bath. Total samples were withdrawn at predetermined time intervals and immediately replaced by an equal volume of fresh medium. Permeation quantities of ropivacaine were determined analyzed by HPLC at 220 nm. Each data point represents the average of three determinations.
The cumulative amount of ropivacaine through the rat skin was plotted against time (min). A linear profi le was observed for 2 h and the slope of the linear portion of the curve was determined by linear regression. The effectiveness of penetration enhancers was defi ned as the enhancement factor (EnF). EnF was calculated using the following equation: EnF = (fl ux of ropivacaine-CMC gels containing enhancers) / (fl ux of the control)
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Tail fl ick anesthetic test
Male Sprague-Dawley rats, 7-8 weeks old (270-300 g), were purchased from Daehan Laboratory Animal Research Co. (Choongbuk, Republic of Korea). The animals were housed (four or fi ve per cage) in laminar fl ow cages maintained at 22 ± 2 o C, a 50-60% relative humidity, and a 12:12 h light-dark cycle. The experiments were carried out in accordance with the "Guiding Principles in the Use of Animals in Toxicology" adopted by the Society of Toxicology (USA) in July 1989 and revised in March 1999. The Animal Care Committee of Chonnam National University (Gwangju, Republic of Korea) approved the study design and procedures.
The heat radiant tail fl ick assay, developed by D'Amour and Smith in the 1940s (D'Amour and Smith, 1941) , is a commonly used experimental model for thermo-pain quantifi cation. In this test, a rodent tail is exposed to a light source (radiant heat) and the latency of tail withdrawal from the heat source is recorded and analyzed. Depending on the experimental settings, the tail fl ick technique can be used to determine the basal nociception level, the analgesic effectiveness of pharmacological agents, and tolerance formation.
The tail fl ick assay remains a valuable method due to its simplicity, reproducibility, its relatively low variation, and the minimal requirement for apparatus. Moreover, a unique feature of tail fl ick versus other thermo-pain quantifi cation methods, such as hot plate or Hargreaves, is that a spinally mediated simple refl ex is primarily, if not exclusively, involved to produce the end-point detection of a fl icking tail (Ossipov and Gebhart, 1996) . Thus the absence of complex behavior (e.g., paw-licking in hot-plate test) renders the tail fl ick method advantageous because it avoids the confounding effects arising from scoring or interpreting more complicated behaviors. In some cases, the tail fl ick test can even be carried out in lightly anesthetized animals (Ness and Gebhart, 1986) .
The rats were divided into four groups containing three rats each: control gel group, ropivacaine gel group, ropivacaine gel containing an enhancer group, ropivacaine gel containing enhancer and vasoconstrictor group.
The rat was fi xed on a tail-fl ick-test apparatus (Tail fl ick anesthetic meter, Harvard Co. Ltd. USA) with the tail, 10 cm from its tip, exposed to heat from a projector lamp. A single control switch simultaneously activated the light and a timer and the timer stops automatically when tail fl icks. The time interval between switching on the light to fl ick of the tail was recorded. A 50 sec cut-off time was used to avoid thermal injury. A dose of 50 mg of drug gels was applied to the root of the tail on the midline. The tail fl ick anesthetic test was started after administration, and the test was done every 5 min until the duration time fell to control value.
The area under the effective curve (AUEC 0→120 min ) from time zero to 120 min of the rat tail fl ick test curve was calculated using the linear trapezoidal rule. The effi cacy factor in local anesthetic effects of ropivacaine after topical application of ropivacaine gel containing polyoxyethylene 2-oleyl ether was compared with that control gel not containing any additives. The effi cacy factor (EfF) was calculated using the following equation: EfF = (AUEC of ropivacaine gels containing enhancer) / (AUEC of the control gel)
RESULTS AND DISCUSSION
Eff ects of CMC concentration on the bioadhesive force and viscosity
The viscosity of various kinds of 100 MC, 150 MC and 300 MC CMC gels at 1.5% concentration was 485, 916 and 1,790 cps, respectively. The bioadhesive force of 100 MC, 150 MC and 300 MC CMC gels at 1.5% concentration was 0.024, 0.046 and 0.083 N, respectively. 150 MC-CMC gels showed the best bioadhesive forces. As the viscosity of the CMC gels increased, the bioadhesive forces increased (Fig. 1) .
Among the various types of CMC, 100 MC gel showed the highest viscosity and bioadhesive force. From these experiments, 100 MC that showed the highest bioadhesive force was chosen as a bioadhesive gel formulation. To develop the new gel formulation that has suitable bioadhesion, the easy determination of viscosity could be used instead of bioadhesive force assessment.
Eff ect of ropivacaine concentration on the drug release
The effect of ropivacaine concentration on drug release across synthetic cellulose membrane was studied from the prepared CMC gels for 2 hour at 37 ± 0.5 o C. The concentrations tested were 0.5, 1, 1.5, 2 and 2.5%, respectively. The fl ux of ropivacaine from the gel formulations through synthetic cellulose membranes (Spectrapor ® MW 12-14,000) for 2 hr was shown in Fig. 2 . As the concentration of ropivacaine from the gels increased, drug release increased. As shown in Fig.  2 , the permeation of drug followed Fick's law and exhibited concentration-dependent passive diffusion. Concerning the viscosity and appearance of the gel, 1.5% concentration of ropivacaine was chosen as an anesthetic gel formulation.
Eff ect of temperature on drug release
The effect of temperature on drug release from the 1.5% ropivacaine gel formulations was evaluated at 27, 32, 37 and 42 o C. All experiments were carried out at least in triplicate. The temperature dependency of drug release as a function of time was shown in Fig. 3. A linear relationship was observed between the logarithm of the permeability coeffi cient (P) and the reciprocal temperature (Fig. 3) . The slope was used to calculate the activation energy (E a ) for drug diffusion. The intercept was used to calculate the pre-exponential term. The permeability coeffi cient is then defi ned by:
As expected from Equation 5, the activation energy (E a ) of drug permeation, which was calculated from the slope of log P versus 1,000/T plot, was 3.16 kcal/mol for a 1.5% loading dose. The observation indicates clearly that the release of drug from the gels is an energy-linked process (Miyazaki et al., 1984) .
Eff ect of enhancers on the permeation of ropivacaine across the rat skin
To increase the skin permeation of ropivacaine from the CMC gel, various enhancers such as saturated and unsaturated fatty acids, pyrrolidones, propylene glycol derivatives, glycerides, and non-ionic surfactants, were incorporated in the ropivacaine-CMC gels. Skin is a complex, dynamic, layered organ that has many functions beyond its role as a barrier to the environment. The highly organized structure of the stratum corneum (SC) forms a barrier to substance penetration. To permeate the skin, the drug must diffuse through the hydrophilic and/or lipophilic environment of the SC to the deeper epidermal layers and to the dermis (Magnusson and Runn, 1999) . However, the SC acts as a barrier and reduces skin permeability during transdermal drug delivery.
Penetration enhancers, accelerants, or promoters can interact with some components of skin to increase fl uidity in the intercellular lipid lamellae, causing the SC to swell and/ or leach out structural components, thus increasing drug penetration through the barrier membrane (Magnusson and Runn, 1999) . The penetration enhancers facilitate the absorption of penetrant through the skin by temporarily increasing the permeability of the skin. Some of the important penetration enhancers as classifi ed by Sinha and Kaur (2000) are www.biomolther.org fatty acids, pyrrolidinones, alcohols, glycerides and polyoxyethylenes. These enhancers are divided into three groups as a manner of mechanism. One mechanism is increased skin/ vehicle partitioning of the drug. It was reported that the permeation enhancement of naphazoline by fatty acids could be caused by ion pair formation between drug and fatty acids, resulting in the increase of partitioning into the stratum corneum (Green and Hadgraft, 1988) . A second likely mechanism of skin permeation enhancement is increased solvent transport into or across the skin. The results of increased solvent penetration may include increased drug solubility in the skin and increased skin penetration of the drug if the drug has a high affi nity for the solvent (Yamada et al., 1987) . The remaining proposed mechanism is increased drug solubility in the vehicle. Generally, acidic enhancers have been used to increase the solubility of basic drugs, and vice versa (Aungust and Rogers, 1980) . Because of their widely different chemical structures, it is likely that the enhancers act by more than one mechanism and that their precise enhancer activity will depend on the physicochemical properties of the penetrant as well as the enhancer (Hadgraft and Walters, 1993 ). An ideal skin penetration enhancer is effective, nonirritating, and reversible (Barry and Bennett, 1987) . Fatty acids are currently receiving much attention as penetration enhancers (Tanojo et al., 1997; Oh et al., 1998) . Fatty acids, by way of interactions with intercellular lipid domains, promote the skin permeation of drugs with a wide range of polarities. The effi cacy of fatty acids is intrinsically linked to their structure, with differences evident between saturated and unsaturated forms and those of different hydrocarbon chain length (Kandimalla et al., 1999) . Unsaturated fatty acids, particularly those of cis conformation and C 18 chain lengths, are more effective enhancers than their saturated counterparts, promoting the permeation of penetrants such as naloxone (Aungust and Rogers, 1980) and fl urbiprofen (Chi et al., 1995) . When compared with a control, a saturated fatty acid group slightly increased the permeation rate. Among the saturated fatty acid group, myristic acid showed the highest permeation rate. Among the unsaturated fatty acids like oleic acid and linoleic acid, oleic acid showed signifi cantly increased permeation of ropivacaine from CMC gel. In the case of fatty acids, a saturated fatty acid group increased the permeation rate more than an unsaturated fatty acid group (Choi and Shin, 2008) .
Surfactants have been reported to enhance the permeability of drugs (Lopez et al., 2000; Shin et al., 2001; Shokri et al., 2001) . They affect the permeability characteristics of several biological membranes, including skin (Florence et al., 1994; Lopez et al., 2000) , and for this reason they can enhance the skin penetration of other compounds present in the formulation. In skin pre-treated with non-ionic surfactant, the SC was loosely layered and the intercellular spaces were wide (Shin et al., 2001; Choi and Shin, 2010) . Therefore, in recent years, surfactants were used to enhance the permeation rates of several drugs. Among the non-ionic surfactants used, polyoxyethylene 2-oleyl ether (Brij 92) showed the greatest enhancing effects (Fig. 4) .
Caprylocaproyl macrogol-glyceride (Labrasol) increases the passive transport of drug molecules. It exhibits high tolerance and low toxicity and included as a pharmaceutical excipient in European Pharmacopoeia (2008) . Oleyl macrogol-6 glyceride (Labrafi l) is a PEG derivative that is biocompatible and biodegradable (Gao et al., 1995) and used as a co-surfactant in pharmaceutical systems such as microemulsions. Among the glycerides, oleyl macrogol-6 glyceride shows a signifi cant permeation rate for ropivacaine. Propylene glycol (PG) is widely used as a vehicle for penetration enhancers and permeates well through the human stratum corneum. PG readily permeates the skin and in so doing may carry the drug molecules across (Adrian and Barry, 2004) .
Pyrrolidones have been used as penetration enhancers in human skin for hydrophilic and lipophilic permeants. In terms of mechanisms of action, the pyrrolidones partition well into the human corneum stratum. Within the tissue, they may act by altering the solvent nature of the membrane and pyrrolidones have been used to generate 'reservoirs' within skin membranes. Such a reservoir effect offers potential for sustained release of a permeant from the stratum corneum over an extended time period (Jungbauer et al., 2001) .
The effects of penetration enhancers on the permeation rate of ropivacaine were determined by comparing the fl ux of drugs in the presence or the absence of enhancers. EnF = (drug fl ux from the gel containing enhancer) / (drug fl ux from the gel without enhancer)
The enhancement factors (EnF) of various enhancers are shown in Table 1 . Among the enhancers tested such as the saturated, the unsaturated fatty acids, the pyrrolidones, the propylene glycol derivatives, the glycerides, and the non-ionic surfactants, polyoxyethylene 2-oleyl ether showed the highest enhancement. Enhancement factor of the ropivacaine gel Fig. 4 . Effect of the non-ionic surfactants on the penetration of ropivacaine from the CMC gels through the excised rat skin. The drug permeation through rat skin from the 1.5% ropivacaine-CMC gel formulations was carried out at 37 o C using phosphate buffer solution (pH 7.4) as a receptor medium. Permeation quantities of ropivacaine were determined analyzed by HPLC at 220 nm. Each data point represents the average of three determinations. containing polyoxyethylene 2-oleyl ether was 2.36 comparing the ropivacaine gel containing the no-enhancer.
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Tail-fl ick anesthetic test of ropivacaine gel containing an enhancer
In percutaneous permeation studies, ropivacaine gel containing polyoxyethylene 2-oleyl ether showed the highest enhancing effects. Therefore, we tested the anesthetic effects of this preparation in a rat tail fl ick analgesic meter. Table 2 shows the AUEC 0→120 min of the rat-tail fl ick test for anesthetic gel.
From the AUEC (Area Under the Effi cacy Curve) of the rat tail fl ick test curve, the value of AUEC of ropivacaine gel containing polyoxyethylene 2-oleyl ether and tetrahydrozoline was 2,960.34 sec . min. The ropivacaine gel containing polyoxyethylene 2-oleyl ether was 2654.84 sec . min, while that not containing any additives was 2066.78 sec . min. The anesthetic effi cacy of ropivacaine gel containing polyoxyethylene 2-oleyl ether showed about 1.43-fold compared with that not containing any additives.
According to the rat tail fl ick test, 1.5% ropivacaine gel containing polyoxyethylene 2-oleyl ether showed the better prolonged anesthetic effects. The ropivacaine gel containing polyoxyethylene 2-oleyl ether showed prolonged, the highest anesthetic effects at 30 min and ropivacaine gel showed at 20 min.
The combination with the vasoconstrictor, tetrahydrozoline, showed similar effi cacy but an even longer anesthetic effect (Fig. 5) . It is suggested that vasoconstrictor localized the ropivacaine concentration on applied area and showed longer anesthetic time.
The rate of drug release increased with increasing drug concentration and temperature. The anesthetic effi cacy of ropivacaine gel containing polyoxyethylene 2-oleyl ether and tetrahydrozoline was 1.43-fold higher than ropivacaine gel not containing additives. These results suggest that a topical gel formulation of ropivacaine containing polyoxyethylene 2-oleyl ether and tetrahydrozoline could be developed for enhanced local anesthetic effects. 
Fig. 5.
Tail fl ick test of 1.5% ropivacaine gels. The rats were divided into four groups containing three rats each: control gel group, ropivacaine gel group, ropivacaine gel containing an enhancer group, ropivacaine gel containing enhancer and vasoconstrictor group. A dose of 50 mg of drug gels was applied to the root of the tail on the midline. The tail fl ick anesthetic test using a tail-fl ick-test apparatus (Tail fl ick anesthetic meter, Harvard Co. Ltd. USA) was started after administration, and the test was done every 5 min until the duration time fell to control value. The area under the effective curve (AUEC 0→120 min ) from time zero to 120 min of the rat tail fl ick test curve was calculated using the linear trapezoidal rule. Each data point represents the average of three determinations.
